SI-BONE, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
SI-BONE reported Q2 2026 worldwide revenue of $56.0M (+15.2% YoY), U.S. revenue $53.2M (+14.7% YoY), gross margin 79.5%, and net loss of $4.1M (improved 33.6% YoY). Adjusted EBITDA turned positive at $2.8M (+178% YoY). The company raised FY2026 guidance to $231–233M revenue (+15–16% growth) and reduced OpEx growth guidance from 12.5% to 12.0%. Active U.S. physicians grew 19% to 1,715. Key catalysts include June 510(k) submission for a third breakthrough device and CMS reimbursement improvement (new MS-DRG effective October 1, 2026).
Why this rating
Meaningful operational momentum—accelerating profitability, raised guidance, new device pipeline, and reimbursement tailwinds are substantive. ~$232M annual revenue guidance is ~29% of $800M market cap; 15–16% growth with OpEx discipline moving toward sustained profitability is material. Not transformational, but real near-term trajectory improvement.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.